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MODEL-BASED COMPARATIVE
PHARMACOECONOMIC ANALYSES OF
BIMATOPROST 0.03% IN THE TREATMENT OF
GLAUCOMA OR OCULAR HYPERTENSION IN
ADULT PATIENTS IN AUSTRIA AND FINLAND
Poulsen PB1, Christensen TL1, Holmstrom S2, Buchholz P3,
Walt JG4
1MUUSMANN Research & Consulting, Kolding, Denmark;
2Allergan, Mougins, France; 3Allergan, Ettlingen, Germany;
4Allergan, Irvine, CA, USA
OBJECTIVES: Glaucoma is a condition affecting one or
both eyes with raised intraocular pressure (IOP). Target
IOP should be reduced to 15mmHg to prevent progres-
sion of visual ﬁeld loss. The objective of the present study
was to perform and compare two country-speciﬁc cost-
effectiveness analyses of bimatoprost 0.03% (Lumigan)
compared with latanoprost 0.005% (Xalatan) as a
second-line mono-therapy for glaucoma patients in
Austria and Finland. METHODS: Revealing identical
practice patterns in glaucoma treatment in Austria and
Finland a decision model based on effectiveness and
resource-use data from a multinational RCT was con-
structed. The RCT covered 269 adult patients with inad-
equately controlled IOP. In the model country-speciﬁc
unit costs were used and cost-effectiveness was analysed
from a societal perspective within a 12-months time
horizon. The measure of effectiveness was “patients
achieving target IOP”. To handle uncertainty sensitivity
analyses (one-way, break-even, extreme scenario) were
undertaken. RESULTS: The RCT showed that 36% of
the patients using bimatoprost achieved target IOP
opposed to 22% using latanoprost. In the Austrian cost-
effectiveness analysis bimatoprost (€2279 per patient
achieving target IOP) showed to be cost-effective com-
pared with latanoprost (€3917). With nearly identical
ratios the same result appeared for Finland (bimatoprost:
€2317; latanoprost: €3998). The relative decrease in the
costs using bimatoprost was therefore 42% in both coun-
tries per patient achieving target IOP. The major reason
to this difference was the extra need for adjunctive ther-
apies using latanoprost. For all IOP-target levels in the
range 12–18mmHg bimatoprost was cheaper and more
effective (dominating strategy). CONCLUSION: Bimato-
prost showed to be a more cost-effective second-line
mono-therapy for glaucoma treatment in Austria and
Finland. The study furthermore showed that at least for
the two countries it seems possible to transfer cost-
effectiveness results between countries and still arrive at
the same recommendations for decision-making.
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ECONOMIC EVALUATION OF PHOTODYNAMIC
THERAPY WITH VERTEPORFIN FOR SMALL
SUBFOVEAL CNV LESIONS:THE CASE OF
AUSTRALIA
Lees M1, Davey PJ1, Price N1,Aldridge G1, Mudge MAC1,
Stokes J2
1Medical Technology Assessment Group, Chatswood West,
NSW, Australia; 2Novartis Ophthalmics, North Ryde, NSW,
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OBJECTIVE: To assess the cost-effectiveness of photo-
dynamic therapy (PDT) with verteporﬁn as treatment for
subfoveal choroidal neovascularisation (CNV) with small
lesions (4 macular photocoagulation study disc areas),
relative to no treatment. METHODS: This analysis
assesses the cost-effectiveness of PDT using verteporﬁn in
patients with small subfoveal CNV lesions, based on
results of two multicentre, double-blind, randomised,
placebo-controlled trials (VIP and TAP). Data on visual
acuity were collected for 24–48 months. Patients with
visual acuity scores above the level of legal blindness in
Australia (which is 34 letters) were deﬁned as not blind.
The proportion of patients not blind at each three-month
interval was plotted on a “vision curve”, which was
extrapolated to 84 months. The area under this curve was
calculated for each group. The difference in the area
under the curve between groups represents the vision-
years gained from treatment. A costing analysis was per-
formed, based on an average of 3.4 treatments in the ﬁrst
year, 2.2 in the second year, 1.3 in the third year and 0.4
in the fourth year. Costs of nursing home, home and com-
munity care, falls and the disability pension considered to
be due to visual decline were also included. RESULTS:
Treatment using PDT with verteporﬁn results in a cost
saving, relative to no treatment, of between $2909 and
$4992 over the 7-year period, depending on assumptions
made in the extrapolation of trial data. Over this period,
between 1.801 and 2.194 vision-years were gained.
Therefore, PDT with verteporﬁn is both less expensive
and more effective than no treatment in this population.
Sensitivity analyses demonstrated these results were
robust to changes in the value of key variables. CON-
CLUSIONS: PDT with verteporﬁn represents a cost-
effective intervention in the proposed population. There
is currently no alternative therapy for patients with small
subfoveal CNV lesions.
PES7
COST-EFFECTIVENESS ANALYSIS OF CATARACT
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Baltussen R
World Health Organisation, Geneva, Switzerland
OBJECTIVES: Cataract is a major cause of blindness and
of severe visual impairment leading to bilateral blind-
ness in an estimated 20 million people worldwide. In
developing countries 50–90% of all blindness is due 
to cataract. There are several possible approaches to
removal of the cataract. This paper reports estimates of
the population health effects, costs and cost-effectiveness
of selected interventions in cataract surgery to restore eye-
sight in areas of the world with different epidemiologic
proﬁles. METHODS: Effectiveness estimates are based on
literature review taking into account factors such as oper-
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ative failure, complications and patient non-compliance.
A population model was applied to follow to the life-long
impact of individuals receiving cataract surgery. Costing
estimates are based on primary data collection in 14 epi-
demiological sub-regions by regional costing teams and
literature review, and were estimated for different cover-
age levels using non-linear cost functions. RESULTS:
Intra- and extra-capsular cataract surgery are cost-
effective ways to reduce the impact of cataract-blindness.
Extra-capsular cataract surgery is more cost-effective
than intra-capsular surgery in all regions considered, and
higher coverage levels are always more cost-effective than
lower coverage levels. Extra-capsular cataract surgery at
a 95% coverage level would avert over 3.8 million dis-
ability adjusted life years per year globally. The cost-
effectiveness ranges from I$69 per DALY in SearD (South
East Asian Region with high child and adult mortality)
to I$2341 per DALY in WprA (Western Paciﬁc Region
with low child and adult mortality). CONCLUSIONS: In
cataract surgery, extra-capsular surgery at high coverage
level is the most cost-effective way for restoring eyesight.
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BURDEN OF ILLNESS OF ECZEMA IN CANADA
Barbeau M, Lalonde H
Novartis Pharma Canada Inc, Dorval, QC, Canada
OBJECTIVES: As no Canadian data exist yet, the objec-
tive of the study is to determine the burden of illness of
patients suffering from eczema in Canada. The resource
use, direct costs, indirect costs, demographics and other
factors affected by eczema were measured over a 1-year
period. METHODS: Patients were recruited through
Community Pharmacists in Canada and were asked to ﬁll
out a four-page survey. Information about gender, age,
marital status, employment status, income, healthcare
practitioner visits, other medical services visits, hospital-
ization, absenteeism at work/school, over-the-counter
(OTC) treatment, household expenses, sleep distur-
bances, severity and duration of the disease, number of
ﬂares and length of each ﬂare and type of insurance cov-
erage were collected. Costs were attached to the different
variables to calculate the burden of illness of eczema for
the whole cohort but the group was also divided by
disease severity. RESULTS: Over 100 patients were
recruited and more than 70 patients have returned the
survey to this point. Each patient has visited a physician
due to his/her eczema at least once in the last 12 months.
The two variables that have had the most impact on the
cost of the disease are the consumption of OTC medica-
tions and the extra household expenses incurred by the
patient. As expected, the burden increases with the sever-
ity of the disease. Nobody was hospitalised due to their
eczema. CONCLUSIONS: Taken individually, the eco-
nomic burden of eczema is not exceptionally high but
given the prevalence of the disease it represents a high
burden for the society. The results are within the range of
what has been published until now. Prescription costs
were not measured directly in this survey and thus the
results are most likely underestimated.
EYE & SKIN DISEASES/DISORDERS—Quality of
Life/Preference Based Outcomes
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A BASELINE ASSESSMENT OF THE VALIDITY OF
THE 39-ITEM NATIONAL EYE INSTITUTE
VISUAL FUNCTION QUESTIONNAIRE IN
GERMAN PATIENTS WITH AGE-RELATED
MACULAR DEGENERATION
Lustig SP1, Reichel MB2, Cappelleri J1, Clouse B1,
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OBJECTIVES: To investigate the validity of the 39-item
National Eye Institute Visual Function Questionnaire
(NEI-VFQ-39) at baseline in German patients with 
age-related macular generation (AMD). METHODS:
Ongoing prospective observational study in which 137
patients attended a clinic in Germany. Patients belonged
to one of 3 severity classes: 1) early AMD in both eyes (n
= 25); 2) late-stage AMD in one eye and early-stage AMD
in the other eye (n = 71); and 3) late-stage AMD in both
eyes (n = 41). Correlations of baseline scores were calcu-
lated between NEI-VFQ-39 and visual acuity. Baseline
mean scores on the NEI-VFQ-39 were compared for dif-
ferent AMD severity using linear regression adjusting for
gender, age, education, and smoking. RESULTS: Scores
on visual acuity correlated moderately, as expected, with
NEI-VFQ-39 domain scores on General Vision (r = 0.48),
Near Activities (r = 0.52), Distant Activities (r = 0.46),
and Peripheral Vision (r = 0.44). As expected, visual
acuity correlated modestly though meaningfully with
Social Functioning (r = 0.31), Mental Health (r = 0.31),
Role Difﬁculties (r = 0.36), Dependency (r = 0.38),
Driving (r = 0.34), and Color Vision (r = 0.30); visual
acuity showed little or no correlation with General Health
(r = 0.13) and Ocular Pain (r = -0.09). Signiﬁcant differ-
ences (p < 0.01) in mean scores among severity levels of
AMD were observed for all NEI-VFQ-39 domains except
for domains on Driving, General Health, and Ocular
Pain. CONCLUSIONS: The German version of the NEI-
VFQ-39 exhibits baseline validity as a measure of func-
tional impairment in patients with AMD.
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PATIENT REPORTED OUTCOMES AND
ECONOMIC IMPLICATIONS OF A
REFORMULATION TO IMPROVE BRIMONIDINE
0.2%
Walt JG, Lee J
Allergan, Irvine, CA, USA
OBJECTIVES: To assess patient satisfaction and eco-
nomic implications associated with a new formulation of
